ORKA
Oruka Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.54 EPS
Last earnings +0.5% on 2026-04-30
$82.09
▼ -1.57%$82.09▲ +585.23%
over 1Y
L $10.90EODHDH $85.38
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.6%
1W+15.8%
1M+39.0%
3M+87.4%
YTD+190.4%
1Y+585.2%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 20 analysts
Strong Buy
Pre-revenue clinical-stage biotech burning $88M/yr at a ~$4B market cap — binary asset with no fundamentals to anchor valuation.
Oruka is a clinical-stage biopharmaceutical company with zero product revenue since inception in February 2024, per the MD&A. The entire investment case rests on two unapproved monoclonal antibody candidates — ORKA-001 (IL-23p19) and ORKA-002 (IL-17A/F) — targeting psoriasis and other I&I indications. The company explicitly states it 'do[es] not have any products approved for sale and ha[s] not generated any revenue from product sales,' and warns it will 'continue to incur substantial losses for the foreseeable future.' This is not a stock you value on fundamentals; it is a venture-stage bet trading on the public market.
Sources: SEC EDGAR (CIK 0000907654, latest 10-Q filed 2026-05-13) · EODHD · analysis by claude-code · as of 6/25/2026, 12:44:56 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.